BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11353634)

  • 21. Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors: evidence for resistance to lamivudine.
    García-Lerma JG; Nidtha S; Heneine W
    J Infect Dis; 2001 Aug; 184(4):507-10. PubMed ID: 11471110
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine.
    Paolucci S; Baldanti F; Campanini G; Cancio R; Belfiore A; Maga G; Gerna G
    Antiviral Res; 2007 Nov; 76(2):99-103. PubMed ID: 17640745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors.
    Saracino A; Monno L; Scudeller L; Cibelli DC; Tartaglia A; Punzi G; Torti C; Lo Caputo S; Mazzotta F; Scotto G; Carosi G; Angarano G
    J Med Virol; 2006 Jan; 78(1):9-17. PubMed ID: 16299731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unusual codon 69 insertions: influence on human immunodeficiency virus type 1 reverse transcriptase drug susceptibility.
    Bulgheroni E; Croce F; Citterio P; Viganò O; Visonà R; Sala E; Galli M; Rusconi S
    J Clin Virol; 2004 Jan; 29(1):27-32. PubMed ID: 14675866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deletions in the beta3-beta4 hairpin loop of HIV-1 reverse transcriptase are observed in HIV-1 isolated from subjects during long-term antiretroviral therapy.
    Ross L; Johnson M; Ferris RG; Short SA; Boone LR; Melby TE; Lanier R; Shaefer M; St Clair M
    J Hum Virol; 2000; 3(3):144-9. PubMed ID: 10881994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.
    Boyer PL; Imamichi T; Sarafianos SG; Arnold E; Hughes SH
    J Virol; 2004 Sep; 78(18):9987-97. PubMed ID: 15331732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication.
    Perez-Olmeda M; Garcia-Perez J; Mateos E; Spijkers S; Ayerbe MC; Carcas A; Alcami J
    J Med Virol; 2009 Feb; 81(2):211-6. PubMed ID: 19107982
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Variants other than aspartic acid at codon 69 of the human immunodeficiency virus type 1 reverse transcriptase gene affect susceptibility to nuleoside analogs.
    Winters MA; Merigan TC
    Antimicrob Agents Chemother; 2001 Aug; 45(8):2276-9. PubMed ID: 11451685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An HIV-1 215V mutant shows increased phenotypic resistance to d4T.
    Pernas M; López-Galíndez C
    Virus Res; 2008 Aug; 135(2):340-4. PubMed ID: 18482778
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors.
    Winters MA; Coolley KL; Girard YA; Levee DJ; Hamdan H; Shafer RW; Katzenstein DA; Merigan TC
    J Clin Invest; 1998 Nov; 102(10):1769-75. PubMed ID: 9819361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
    Marcelin AG; Delaugerre C; Wirden M; Viegas P; Simon A; Katlama C; Calvez V
    J Med Virol; 2004 Jan; 72(1):162-5. PubMed ID: 14635026
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect.
    Jeeninga RE; Keulen W; Boucher C; Sanders RW; Berkhout B
    Virology; 2001 May; 283(2):294-305. PubMed ID: 11336554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database.
    McColl DJ; Chappey C; Parkin NT; Miller MD
    Antivir Ther; 2008; 13(2):189-97. PubMed ID: 18505170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An additive/subtractive genotypic score as a determinant of the virological response to didanosine in HIV-1 infected patients.
    Capdepont S; Aurillac-Lavignolle V; Faure M; Dupon M; Morlat P; Ragnaud JM; Chêne G; Fleury H; Masquelier B;
    J Clin Virol; 2006 May; 36(1):36-42. PubMed ID: 16513416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutational patterns associated with the 69 insertion complex in multi-drug-resistant HIV-1 reverse transcriptase that confer increased excision activity and high-level resistance to zidovudine.
    Cases-González CE; Franco S; Martínez MA; Menéndez-Arias L
    J Mol Biol; 2007 Jan; 365(2):298-309. PubMed ID: 17070543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug susceptibility of human immunodeficiency virus type 1-derived pseudoviruses from treatment-experienced patients to protease inhibitors and reverse transcriptase inhibitors, using a modified single-round assay.
    Choi JY; Kwon OK; Choi SY; Park YK; Kim SS
    J Clin Virol; 2011 Jan; 50(1):19-25. PubMed ID: 20970373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. AZT-related mutation Lys70Arg in reverse transcriptase of human immunodeficiency virus type 1 confers decrease in susceptibility to ddATP in in vitro RT inhibition assay.
    Sharma PL; Chatis PA; Dogon AL; Mayers DL; McCutchan FE; Page C; Crumpacker CS
    Virology; 1996 Sep; 223(2):365-9. PubMed ID: 8806572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fast genotypic detection of drug resistance mutations in the HIV-1 reverse transcriptase gene of treatment-naive patients.
    Fontaine E; Lambert C; Servais J; Ninove D; Plesséria JM; Staub T; Arendt V; Kirpach P; Robert I; Schneider F; Hemmer R; Schmit JC
    J Hum Virol; 1998; 1(7):451-6. PubMed ID: 10195266
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of discrepancies in the interpretation of antiretroviral drug resistance results in HIV-1 infected patients of Basque Country, Spain.
    Muñoz M; Carmona R; Pérez-Alvarez L; Cilla G; Suarez MD; Delgado E; Contreras G; Corral J; de Goicoetxea MJ; Medrano L; Lezaún MJ; Nájera R;
    J Clin Virol; 2005 Jul; 33(3):224-9. PubMed ID: 15911444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.